1-15 of 15
Eytan Stein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Hanny Al-Samkari, Pierre Fenaux, Mikkael A. Sekeres, Eytan Stein, David A. Sallman, Andrew M. Brunner, Xiaoshu D. Gurov, Ophelia Yin, Meghan Frisbie, James Xiao, Joy Bhatia, Vanessa Beynon, Megan Wind-Rotolo, Melissa Dibacco, Uwe Platzbecker
Journal: Blood
Blood (2022) 140 (Supplement 1): 4076–4078.
https://doi.org/10.1182/blood-2022-168907
Published: 2022
Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Uma Borate, Rui Li, Ying Huang, Ronan T. Swords, Elie Traer, Eytan Stein, James M. Foran, Maria R. Baer, Vu H. Duong, Wendy Stock, Olatoyosi Odenike, Prapti Patel, Robert H. Collins, Yazan F. Madanat, Tibor Kovacsovics, Michael W. Deininger, Catherine Smith, Rebecca L. Olin, Martha L. Arellano, William G. Blum, Gary J. Schiller, Tara L. Lin, Matthew C. Foster, Michael M. Boyiadzis, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Theophilus J Gana, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 6200–6203.
https://doi.org/10.1182/blood-2022-167316
Published: 2022
Journal Articles

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Brian J Ball, Eytan Stein, Marjorie Robbins, Jianying Zhang, Ross L. Levine, Timothy Synold, Anthony S. Stein, Guido Marcucci, Yilun Liu, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 11761–11762.
https://doi.org/10.1182/blood-2022-170820
Published: 2022
Journal Articles

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 3333–3335.
https://doi.org/10.1182/blood-2022-156564
Published: 2022
Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Ghayas C. Issa, Branko Cuglievan, Eytan Stein, Martha L. Arellano, Andrius Žucenka, Nandita Khera, Richard M. Stone, Michael J. Thirman, John F. DiPersio, Nicole Karras, Yu Gu, Rebecca G. Bagley, Galit Rosen, David Tamang, Kimberly Dishman, Sushama Scalera, Michael L. Meyers, Kate Madigan, Nicole McNeer, Ibrahim Aldoss
Journal: Blood
Blood (2022) 140 (Supplement 1): 914–916.
https://doi.org/10.1182/blood-2022-164600
Published: 2022
Journal Articles

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan
Journal: Blood
Blood (2022) 140 (Supplement 1): 732–734.
https://doi.org/10.1182/blood-2022-158967
Published: 2022
Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Mary Johnson, Ying Huang, Ronan T. Swords, Eytan Stein, James M. Foran, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Tibor Kovacsovics, Rebecca L. Olin, William G. Blum, Gary J. Schiller, Tara L. Lin, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, Uma Borate, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 9070–9073.
https://doi.org/10.1182/blood-2022-166715
Published: 2022
Journal Articles

A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Jan Philipp Bewersdorf, Maximilian F. Stahl, Justin Taylor, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Victoria Kostantakis, Sydney X. Lu, Jessie Bourcier, Simon Hogg, Tulasigeri M Totiger, Omar Abdel-Wahab, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 9065–9067.
https://doi.org/10.1182/blood-2022-156830
Published: 2022
Journal Articles

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia

Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A. Podoltsev, Maximilian F. Stahl, Jessica M. Stempel, Eytan Stein, Scott F. Huntington, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 319–321.
https://doi.org/10.1182/blood-2022-158465
Published: 2022
Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Eytan Stein, Sheng F Cai, Ying Huang, Andrew Dunbar, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Michael M. Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail B. Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine
Journal: Blood
Blood (2022) 140 (Supplement 1): 2016–2019.
https://doi.org/10.1182/blood-2022-166850
Published: 2022
Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Karthik Nath, Jasme Lee, Theresa A Elko, Lauren Levy, Elaina Preston, Sean M. Devlin, Doris M Ponce, Richard J. Lin, Brian C. Shaffer, Christina Cho, Ioannis Politikos, Ann A Jakubowski, Jae H Park, Raajit Rampal, Miguel-Angel Perales, Martin S. Tallman, Juliet N. Barker, Sergio A Giralt, Ellin Berman, Roni Tamari, Eytan Stein, Boglarka Gyurkocza
Journal: Blood
Blood (2022) 140 (Supplement 1): 2137–2139.
https://doi.org/10.1182/blood-2022-157193
Published: 2022
Journal Articles

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Peter Westervelt, Partow Kebriaei, Mark Juckett, Andrew S. Artz, Onyee Chan, Philip L. McCarthy, Sherif S Farag, Anurag K. Singh, Eytan Stein, Jeffrey Humphrey, William Baeder, Ji Hyun Lee, Alison Occhiuti, Jeanie Tang, David Santos, Kirk Bertelsen, Balaji Mahender, Nicole Henry, Shawn Rose
Journal: Blood
Blood (2022) 140 (Supplement 1): 2117–2119.
https://doi.org/10.1182/blood-2022-162406
Published: 2022
Journal Articles

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio, Branko Cuglievan, Richard M. Stone, Martha L. Arellano, Michael J. Thirman, Manish R. Patel, David Dickens, Shalini Shenoy, Neerav Shukla, Galit Rosen, Rebecca G. Bagley, Michael L. Meyers, Kate Madigan, Peter Ordentlich, Yu Gu, Steven Smith, Gerard M. McGeehan, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 150–152.
https://doi.org/10.1182/blood-2022-164849
Published: 2022
Journal Articles

Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Jan Philipp Bewersdorf, Srdan Verstovsek, Andriy Derkach, Lucia Masarova, Naveen Pemmaraju, Eytan Stein, Michael Mauro, Raajit K Rampal, Prithviraj Bose
Journal: Blood
Blood (2022) 140 (Supplement 1): 6844–6846.
https://doi.org/10.1182/blood-2022-158678
Published: 2022
Journal Articles

Siremadlin in Combination with Venetoclax (VEN) Plus Azacitidine (AZA) in Adult Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy: A Phase Ib/II Trial

Naval Daver, Andrew H. Wei, Eytan Stein, Daniel J. DeAngelo, Dhrubajyoti Pathak, Yunnan Xu, Stephanie Grzesiak, Adriano Venditti
Journal: Blood
Blood (2022) 140 (Supplement 1): 11625–11627.
https://doi.org/10.1182/blood-2022-167326
Published: 2022